Journal of the Neurological Sciences
Volume 313, Issue 1 , Pages 22-26 , 15 February 2012

Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: A pilot study

  • Tomomi Nakamura

      Affiliations

    • Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan
    • Itabashi Chuo Medical Center, Tokyo, Japan
    • Corresponding Author InformationCorresponding author at: Department of Neurology, Neurological Institute, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. Tel.: +81 3 3353 8111; fax: +81 3 5269 7324.
    • ,
  • Shinji Tsuruta

      Affiliations

    • Itabashi Chuo Medical Center, Tokyo, Japan
    • ,
  • Shinichiro Uchiyama

      Affiliations

    • Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan

Received 2 July 2011 ,Revised 24 September 2011 ,Accepted 28 September 2011.

References 

  1. Umekawa H, Tanaka T, Kimura Y, Hidaka H. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography. Biochem Pharmacol. 1984;33:3339–3344
  2. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 1985;35:1144–1149
  3. Goto F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2000;9:147–157
  4. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al. Cilostazol for the prevention of secondary stroke (CSPS2): an aspirin-controlled, double-blind, randomized non-inferiority trial. Lancet Neurol. 2010;9:959–968
  5. Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol. 2008;7:494–499
  6. Kamal AK, Naqvi I, Husain MR, Khealani BA. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin (review). Cochrane Database Syst Rev. 2011;CD008076
  7. Chen ZM, Sandercock P, Pan H, Counsell C, Collins R, Liu L, et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the Chinese acute stroke trial and the international stroke trial. Stroke. 2000;31:1240–1249
  8. Buchanan MR, Schwartz L, Bourassa M, Brister SJ, Peniston CM. Results of the BRAT study: a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol. 2000;16:1385–1390
  9. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961–965
  10. Mirkhel A, Peyster E, Sundeen J, Greene L, Michelson AD, Hasan A, et al. Frequency of aspirin resistance in a community hospital. Am J Cardiol. 2006;98:577–579
  11. Uchiyama S, Nakamura T, Yamazaki M, Kimura Y. New modalities and aspects of antiplatelet therapy for stroke prevention. Cerebrovasc Dis. 2006;21(suppl 1):7–16
  12. Roden-Julling A. Progressing stroke: epidemiology. Cerebrovasc Dis. 1997;7(suppl 5):2–5
  13. Toni D, Fiorelli M, Gentile M, Bastianello S, Sacchetti ML, Argentino C, et al. Progressing neurological deficit secondary to acute ischemic stroke. A study on predictability, pathogenesis, and prognosis. Arch Neurol. 1995;52:670–675
  14. Steinke W, Ley SC. Lacunar stroke is the major cause of progressive motor deficits. Stroke. 2002;33:1510–1516
  15. Yamamoto Y, Ohara T, Hamanaka M, Hosomi A, Tamura A, Akiguchi I, et al. Predictive factors for progressive motor deficits in penetrating artery infarctions in two different arterial territories. J Neurol Sci. 2010;288:170–174
  16. Nakamura T, Houchi H, Minami A, Sakamoto S, Tsuchiya K, Niwa Y, et al. Endothelium-dependent relaxation by cilostazol, a phosphodiesterase III inhibitor, on rat thoracic aorta. Life Sci. 2001;69:1709–1715
  17. Nakamura K, Ikomi F, Ohhashi T. Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles. J Vasc Res. 2006;43:86–94
  18. Iida H, Iida M, Takenaka M, Fukuoka N, Dohi S. Comparative effects of cilostazol and aspirin on the impairment of endothelium-dependent cerebral vasodilation caused by acute cigarette smoking rats. J Thromb Thrombolysis. 2010;29:483–488
  19. Hashimoto A, Miyakoda G, Hirose Y, Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis. 2006;189:350–357
  20. Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kurabayashi M, et al. Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-κB binding to its recognition sequence. Atherosclerosis. 2001;158:121–128
  21. Woo SK, Kang WK, Kwon KI. Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans. Clin Pharmacol Ther. 2002;71:246–252
  22. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41
  23. Adams HP, del Zoppo GJ, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke. A guideline from the American Heart Association/American Stroke Association stroke council, clinical cardiology council, cardiovascular radiology and intervention council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups. Stroke. 2007;38:1655–1711
  24. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 1992;20:900–906
  25. Nonaka Y, Tsuruma K, Shimazawa M, Yoshimura S, Iwama T, Hara H. Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage. Neurosci Lett. 2009;452:156–161
  26. Honda F, Imai H, Ishikawa M, Kubota C, Shimizu T, Fukunaga M, et al. Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia. Stroke. 2006;37:223–228
  27. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  28. Howard PA. Aspirin resistance. Ann Pharmacother. 2002;36:1620–1624
  29. Marquardt L, Ruf A, Mansmann U, Winter R, Schuler M, Buggle F, et al. Course of platelet activation markers after ischemic stroke. Stroke. 2002;33:2570–2574
  30. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet. 2004;364:331–337
  31. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomized controlled pilot trial. Lancet Neurol. 2007;6:961–969
  32. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339
  33. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. PRoFESS study group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238–1251
  34. Meyer DM, Albright KC, Allison TA, Grotta JC. LOAD: a pilot study of the safety of loading of aspirin and clopidogrel in acute ischemic stroke and transient ischemic attack. J Stroke Cerebrovasc Dis. 2008;17:26–29
  35. Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg. 2003;38:710–713
  36. Uchiyama S, Demaerschalk BM, Goto S, Shinohara Y, Gotoh F, Stone WM, et al. Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis. 2009;18:482–490

PII: S0022-510X(11)00600-9

doi: 10.1016/j.jns.2011.09.038

Journal of the Neurological Sciences
Volume 313, Issue 1 , Pages 22-26 , 15 February 2012

Article Tools

* Image Usage & Resolution